Diabetes Technology & Therapeutics Journal uri icon
Overview
publication venue for
  • A comparison of continuous glucose monitoring-measured time-in-range 70-180 mg/dL versus time-in-tight-range 70-140 mg/dL 2024
  • A scalable application of artificial intelligence-driven insulin titration program to transform type 2 diabetes management 2024
  • Continuous glucose monitoring metrics and hemoglobin A1c relationship in patients with type 2 diabetes treated by hemodialysis 2024
  • Continuous glucose monitoring prediction of gestational diabetes mellitus and perinatal complications 2024
  • Expert panel recommendations for a standardized ambulatory glucose profile report for connected insulin pens 2024
  • Glycemic outcomes persist for up to 2 years in very young children with the Omnipod(®) 5 Automated Insulin Delivery System 2024
  • Time in range, time in tight range, and average glucose relationships are modulated by glycemic variability: identification of a glucose distribution model connecting glycemic parameters using real-world data 2024
  • Two years with a tubeless automated insulin delivery system: a single-arm multicenter trial in children, adolescents, and adults with Type 1 diabetes 2024
  • A comparison of continuous glucose monitoring estimated hemoglobin A1c in adults with type 1 or type 2 diabetes 2023
  • Assessment of the glucose management indicator using different sampling durations 2023
  • Discordance between glucose management indicator and glycated hemoglobin in people without diabetes 2023
  • Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial 2023
  • Increased derived time in range is associated with reduced risk of major adverse cardiovascular events, severe hypoglycemia, and microvascular events in type 2 diabetes: a post hoc analysis of DEVOTE 2023
  • Safety and glycemic outcomes during the MiniMed(TM) advanced hybrid closed-loop system pivotal trial in children and adolescents with type 1 diabetes 2023
  • The relationship between percent time <70 mg/dL and percent time <54 mg/dL measured by continuous glucose monitoring 2023
  • A comparison of postprandial glucose control in the Medtronic advanced hybrid closed-loop system versus 670G 2022
  • Benefit of continuous glucose monitoring in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes 2022
  • Impact of temporary glycemic target use in the hybrid and advanced hybrid closed-loop systems 2022
  • Real-world evidence supporting Tandem Control-IQ Hybrid Closed-Loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations 2022
  • Safety and glycemic outcomes during the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in adolescents and adults with type 1 diabetes 2022
  • The optimal duration of a run-in period to initiate continuous glucose monitoring for a randomized trial 2022
  • Continuous glucose monitoring integration for remote diabetes management: virtual diabetes care with case studies 2021
  • First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes 2021
  • Lived experience of advanced hybrid closed-loop versus hybrid closed-loop: patient-reported outcomes and perspectives 2021
  • Lost in translation: a disconnect between the science and Medicare coverage criteria for continuous subcutaneous insulin infusion 2021
  • Real-world, patient-reported and clinic data from individuals with type 1 diabetes using the MiniMed 670G hybrid closed-loop system 2021
  • Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a virtual diabetes clinic 2021
  • The digital/virtual diabetes clinic: the future Is now-recommendations from an international panel on diabetes digital technologies introduction 2021
  • Ultrarapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system 2021
  • Ultra-rapid lispro improves postprandial glucose control and time in range in type 1 diabetes compared to lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy 2020
  • Current status and future directions for electronic point-of-care clinical decision support to improve diabetes management in primary care 2019
  • Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen 2019
  • Rationale and design for a GRADE substudy of continuous glucose monitoring 2019
  • State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018 2019
  • The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set 2019
  • Optimal sampling duration for continuous glucose monitoring to determine long-term glycemic control 2018
  • Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes 2017
  • Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes 2016
  • Hypoglycemia in older adults with type 1 diabetes 2016
  • Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP) 2013
  • Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study 2012
  • Can a tool that automates insulin titration be a key to diabetes management? 2012
  • Health-related quality of life and treatment satisfaction in the Sensor-Augmented Pump Therapy for A1C Reduction 3 (STAR 3) trial 2012
  • Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience 2011
  • Comparison of a novel insulin bolus-patch with pen/syringe injection to deliver mealtime insulin for efficacy, preference, and quality of life in adults with diabetes: a randomized, crossover, multicenter study 2011
  • International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, Greece 2011
  • A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial 2009
  • Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System 2009
  • Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes? 2009
  • Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring (CGM): is CGM ready for real time? 2009
  • Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, 2nd Annual Symposium, May 7-10, 2009, Berlin, Germany 2009
  • Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis 2008
  • Impact of modem-transferred blood glucose data on clinician work efficiency and patient glycemic control 2005
  • Making sense of glucose monitoring technologies: from SMBG to CGM 2005
  • Novel pattern identification through standardized data display using the ambulatory glucose profile (AGP) report [abstract] 2016
  • Continuous glucose monitoring for type 2 diabetes: how does it compare with type 1 diabetes [editorial]?.  24. 2022
  • Decreasing the burden of carbohydrate counting and meal announcement with automated insulin delivery, meal recognition, and autocorrection doses: a case study [review] 2024
  • Is it time to move beyond TIR to TITR? Real-world data from over 20,000 users of continuous glucose monitoring in patients with type 1 and type 2 diabetes [review] 2024
  • Primary care and diabetes technologies and treatments [review] 2024
  • Coverage for continuous glucose monitoring for individuals with type 2 diabetes treated with nonintensive therapies: an evidence-based approach to policymaking [review] 2023
  • Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator [review] 2023
  • Prevalence, cost, and burden of diabetic ketoacidosis [review] 2023
  • Primary care and diabetes technologies and treatments [review] 2023
  • Primary care and diabetes technologies and treatments [review] 2022
  • Comparison of second-generation basal insulin analogs: a review of the evidence from continuous glucose monitoring [review] 2021
  • Primary care and diabetes technologies and treatments [review] 2021
  • What's wrong with this picture? A critical review of current Centers for Medicare & Medicaid Services coverage criteria for continuous glucose monitoring [review] 2021
  • Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice [review] 2019
  • Clinical use of continuous glucose monitoring in adults with type 2 diabetes [review] 2017
  • Role of continuous glucose monitoring in clinical trials: recommendations on reporting [review] 2017
  • Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM) [review] 2008